Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0703966Aexternal-prioritypatent/GB2447014A/en
Application filed by Rb Pharmaceuticals LtdfiledCriticalRb Pharmaceuticals Ltd
Publication of NZ616264ApublicationCriticalpatent/NZ616264A/en
Disclosed herein is an analgesic composition, in parenteral unit dosage form or in a unit dosage form suitable for delivery via the dermis or mucosa, comprises buprenorphine and an amount of naltrexone such that the ratio by weight of buprenorphine to naltrexone delivered to or reaching the plasma of a patient is in the range 100:1 to 5000:1. The analgesic action of the buprenorphine is potentiated by the low dose of naltrexone. Also provided are a method of treatment of pain and the use of buprenorphine and naltrexone for the manufacture of a medicament.
NZ616264A2007-03-012008-02-15Improvements in and relating to medicinal compositions for analgesia comprising buprenorphine and naltrexone
NZ616264A
(en)
Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
Pharmaceutical composition comprising acyclovir and a delivery agent, a dosage unit, use of acyclovir in the preparation of the pharmaceutical composition, use of the pharmaceutical composition in the preparation of a medicament and a method of preparing the pharmaceutical composition
Legal Events
Date
Code
Title
Description
PSEA
Patent sealed
RENW
Renewal (renewal fees accepted)
Free format text:
PATENT RENEWED FOR 4 YEARS UNTIL 15 FEB 2016 BY AJ PARK
Effective date:
20150316
RENW
Renewal (renewal fees accepted)
Free format text:
PATENT RENEWED FOR 1 YEAR UNTIL 15 FEB 2017 BY COMPUTER PACKAGES INC